Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
03:55pm, Thursday, 13'th Mar 2025
AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million up
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:01am, Thursday, 13'th Mar 2025
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Calls of the Day: United Airlines, Delta, IBM, Abbvie, Uber
01:39pm, Wednesday, 12'th Mar 2025
The Investment Committee debate the latest Calls of the Day.
Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.
07:10am, Wednesday, 12'th Mar 2025
I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different.
Why AbbVie (ABBV) Dipped More Than Broader Market Today
06:50pm, Tuesday, 11'th Mar 2025
In the latest trading session, AbbVie (ABBV) closed at $213.59, marking a -1.42% move from the previous day.
AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript)
01:14pm, Tuesday, 11'th Mar 2025
AbbVie Inc. (NYSE:ABBV ) Leerink Partners Global Healthcare Conference March 11, 2025 8:40 AM ET Company Participants Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar -
Siri & Glimstad Defeats AbbVie's Motion to Dismiss Illinois GIPA Lawsuit
01:00pm, Tuesday, 11'th Mar 2025
Call to Action: Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
07:57am, Monday, 10'th Mar 2025
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity thera
3 Cheap Stocks to Buy With Your Tax Refund Check
05:30am, Friday, 07'th Mar 2025
The average tax refund in 2024 was $3,138, which was similar to the $3,167 it averaged the previous year. While tax refunds will vary depending on a person's individual financial situation, if you rec
2 Dividend Stocks to Buy for a Lifetime of Passive Income
05:03am, Friday, 07'th Mar 2025
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
02:59pm, Wednesday, 05'th Mar 2025
AbbVie Inc. (NYSE:ABBV ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Company Participants Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R.
Here's How to Play AbbVie Stock as it Enters the Obesity Space
09:40am, Wednesday, 05'th Mar 2025
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
The Dividend Aristocrats Ranked By Quality Scores: March 2025
09:00am, Wednesday, 05'th Mar 2025
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overval
Healthy Returns: AbbVie is the newest potential weight loss drug market player
02:59pm, Tuesday, 04'th Mar 2025
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.
AbbVie to Present at the Leerink Partners Global Healthcare Conference
08:00am, Tuesday, 04'th Mar 2025
NORTH CHICAGO, Ill. , March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025.
